poisar

Stocks · News reference

Why Is Nuvation Bio Stock Gaining Monday?

BenzingaJul 20, 2026, 3:44 PMVandana Singh

Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 20, 2026, 3:44 PM
Checked
Jul 20, 2026, 3:44 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading